JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia

Sandrine Degryse; Jan Cools

doi:10.1186/s13045-015-0192-7

JAK kinase inhibitors for the treatment of acute lymphoblastic leukemia

J Hematol Oncol. 2015 Jul 26:8:91. doi: 10.1186/s13045-015-0192-7.

Authors

Sandrine Degryse^{1

2}, Jan Cools^{3

4

5}

Affiliations

¹ VIB Center for the Biology of the Disease, Leuven, Belgium. sandrine.degryse@cme.vib-kuleuven.be.
² KU Leuven Center for Human Genetics, Leuven, Belgium. sandrine.degryse@cme.vib-kuleuven.be.
³ VIB Center for the Biology of the Disease, Leuven, Belgium. jan.cools@cme.vib-kuleuven.be.
⁴ KU Leuven Center for Human Genetics, Leuven, Belgium. jan.cools@cme.vib-kuleuven.be.
⁵ , Herestraat 49 (Box 602), 3000, Leuven, Belgium. jan.cools@cme.vib-kuleuven.be.

Abstract

Recent studies of acute lymphoblastic leukemia have identified activating mutations in components of the interleukin-7 receptor complex (IL7R, JAK1, and JAK3). It will be of interest to investigate both JAK1 and JAK3 kinase inhibitors as targeted agents for these leukemias.

MeSH terms

Animals
Disease Models, Animal
Humans
Janus Kinase 1 / genetics*
Mice
Oncogenes
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
Receptors, Cytokine
Signal Transduction

Substances

Receptors, Cytokine
JAK1 protein, human
Janus Kinase 1